I agree that this could be a great buying opp if it drifts down to or below the .315 offer price. IMNP certainly can't be accused of over-producing. The Amiket situation is fuzzy at best...far from the sale IMNP forecast more than a year ago.
May 31, 2016 New drugs are on the horizon for the treatment of severe eczema. FDA could approve at least two new eczema medications in 2017, while six more treatments are undergoing clinical tests. Eczema affects about 12% of children in the United States and 7%–10% of adults, according to estimates.
New drugs are on the horizon for the treatment of severe eczema. FDA could approve at least two new eczema medications in 2017, while six more treatments are undergoing clinical tests. Eczema affects about 12% of children in the United States and 7%–10% of adults, according to estimates. While the condition is most common in children and often disappears on its own prior to adolescence, many adults also have eczema, including some 1.6 million with severe forms of the disease that can negatively affect their emotional and mental health.